 II. To determine plasma and tissue levels of atorvastatin and two of its hydroxylated metabolites ohydroxyatorvastatin and p-hydroxyatorvastatin in women who are treated with atorvastatin and to correlate these levels with Ki-67 levels. III. To correlate changes in Ki-67 and the above-described panel of biomarkers with HMG-CoA reductase genotype. 